ArticleBMC cancer2021

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer.

Antoine Adenis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.